Search Results - "Rudd, Stacey"

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides by Morgan, Katherine A, Rudd, Stacey E, Noor, Asif, Donnelly, Paul S

“…Molecular changes in malignant tissue can lead to an increase in the expression levels of various proteins or receptors that can be used to target the disease…”
Get full text

Diagnostic Positron Emission Tomography Imaging with Zirconium-89 Desferrioxamine B Squaramide: From Bench to Bedside by Rudd, Stacey E., Noor, Asif, Morgan, Katherine A., Donnelly, Paul S.

“…Conspectus Molecular imaging with antibodies radiolabeled with positron-emitting radionuclides combines the affinity and selectivity of antibodies with the…”
Get full text

A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies by Rudd, Stacey E, Roselt, Peter, Cullinane, Carleen, Hicks, Rodney J, Donnelly, Paul S

“…A squaramide ester derivative of desferrioxamine B (H DFO) that is compatible with aqueous solvents and does not induce antibody aggregation is used to attach…”
Get more information

Copper(II) Complexes of 2,2'- Bis dipyrrins: Synthesis, Characterization, Cell Uptake, and Radiolabeling with Copper-64 by Rowan, Jacob A, Rudd, Stacey E, Ganio, Katherine, McDevitt, Christopher A, White, Jonathan M, Donnelly, Paul S

“…Complexes prepared with positron-emitting copper-64 are of interest as imaging agents for positron emission tomography (PET). This work investigates the…”
Get full text

Copper(II) Complexes of 2,2′-Bisdipyrrins: Synthesis, Characterization, Cell Uptake, and Radiolabeling with Copper-64 by Rowan, Jacob A., Rudd, Stacey E., Ganio, Katherine, McDevitt, Christopher A., White, Jonathan M., Donnelly, Paul S.

“…Complexes prepared with positron-emitting copper-64 are of interest as imaging agents for positron emission tomography (PET). This work investigates the…”
Get full text

PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study by Hegi-Johnson, Fiona, Rudd, Stacey E., Wichmann, Christian W., Akhurst, Tim, Roselt, Peter, Sursock, Sandra, Trinh, Jenny, John, Thomas, Devereux, Lisa, Donnelly, Paul S., Hicks, Rodney J., Scott, Andrew M., Steinfort, Daniel, Fox, Stephen, Blyth, Benjamin, Parakh, Sagun, Hanna, Gerard G., Callahan, Jason, Burbury, Kate, MacManus, Michael

Get full text

Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer by Noor, Asif, Van Zuylekom, Jessica K, Rudd, Stacey E, Waldeck, Kelly, Roselt, Peter D, Haskali, Mohammad B, Wheatcroft, Michael P, Yan, Eddie, Hicks, Rodney J, Cullinane, Carleen, Donnelly, Paul S

“…Prostate-specific membrane antigen (PSMA) is a carboxypeptidase that is overexpressed in prostate cancer and is an excellent candidate for targeted diagnostic…”
Get full text

Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo by Wichmann, Christian W., Poniger, Stan, Guo, Nancy, Roselt, Peter, Rudd, Stacey E., Donnelly, Paul S., Blyth, Benjamin, Van Zuylekom, Jessica, Rigopoulos, Angela, Burvenich, Ingrid J.G., Morandeau, Laurence, Mohamed, Shifaza, Nowak, Anna K., Hegi-Johnson, Fiona, MacManus, Michael, Scott, Andrew M.

“…89Zr-labelled proteins are gaining importance in clinical research in a variety of diseases. To date, no clinical study has been reported that utilizes an…”
Get full text

Imaging Somatostatin Positive Tumors with Tyr3‑Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68 by Noor, Asif, Van Zuylekom, Jessica K, Rudd, Stacey E, Roselt, Peter D, Haskali, Mohammad B, Yan, Eddie, Wheatcroft, Michael, Hicks, Rodney J, Cullinane, Carleen, Donnelly, Paul S

“…Radiolabeled derivatives of Tyr3-octreotide and Tyr3-octreotate, synthetic analogues of the peptide hormone somatostatin, can be used for positron emission…”
Get full text

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor by Rudd, Stacey E, Van Zuylekom, Jessica K, Raicevic, Anna, Pearce, Lesley A, Cullinane, Carleen, Williams, Charlotte C, Adams, Timothy E, Hicks, Rodney J, Donnelly, Paul S

“…Identification of tumors which over-express Epidermal Growth Factor Receptor (EGFR) is important in selecting patients for anti-EGFR therapies. Enzymatic…”
Get full text

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89 Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol by Hegi-Johnson, Fiona, Rudd, Stacey E, Wichmann, Christian, Akhurst, Tim, Roselt, Peter, Trinh, Jenny, John, Thomas, Devereux, Lisa, Donnelly, Paul S, Hicks, Rod, Scott, Andrew M, Steinfort, Daniel, Fox, Stephen, Blyth, Benjamin, Parakh, Sagun, Hanna, Gerard G, Callahan, Jason, Burbury, Kate, MacManus, Michael

Get full text

Imaging Somatostatin Positive Tumors with Tyr 3 -Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68 by Noor, Asif, Van Zuylekom, Jessica K, Rudd, Stacey E, Roselt, Peter D, Haskali, Mohammad B, Yan, Eddie, Wheatcroft, Michael, Hicks, Rodney J, Cullinane, Carleen, Donnelly, Paul S

“…Radiolabeled derivatives of Tyr -octreotide and Tyr -octreotate, synthetic analogues of the peptide hormone somatostatin, can be used for positron emission…”
Get full text

Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models by Liapis, Vasilios, Tieu, William, Wittwer, Nicole L., Gargett, Tessa, Evdokiou, Andreas, Takhar, Prab, Rudd, Stacey E., Donnelly, Paul S., Brown, Michael P., Staudacher, Alexander H.

“…Purpose Early detection of tumor treatment responses represents an unmet clinical need with no approved noninvasive methods. DAB4, or its chimeric derivative,…”
Get full text

A Versatile Approach for the Site-Specific Modification of Recombinant Antibodies Using a Combination of Enzyme-Mediated Bioconjugation and Click Chemistry by Alt, Karen, Paterson, Brett M., Westein, Erik, Rudd, Stacey E., Poniger, Stan S., Jagdale, Shweta, Ardipradja, Katie, Connell, Timothy U., Krippner, Guy Y., Nair, Ashish K. N., Wang, Xiaowei, Tochon-Danguy, Henri J., Donnelly, Paul S., Peter, Karlheinz, Hagemeyer, Christoph E.

“…A unique two‐step modular system for site‐specific antibody modification and conjugation is reported. The first step of this approach uses enzymatic…”
Get full text

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB by Liapis, Vasilios, Tieu, William, Rudd, Stacey E., Donnelly, Paul S., Wittwer, Nicole L., Brown, Michael P., Staudacher, Alexander H.

“…Purpose The chimeric monoclonal antibody (mAb) chDAB4 (APOMAB®) targets the Lupus associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in…”
Get full text

Imaging immunity in patients with cancer using positron emission tomography by Hegi-Johnson, Fiona, Rudd, Stacey, Hicks, Rodney J., De Ruysscher, Dirk, Trapani, Joseph A., John, Thomas, Donnelly, Paul, Blyth, Benjamin, Hanna, Gerard, Everitt, Sarah, Roselt, Peter, MacManus, Michael P.

“…Immune checkpoint inhibitors and related molecules can achieve tumour regression, and even prolonged survival, for a subset of cancer patients with an…”
Get full text

Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models by Liapis, Vasilios, Tieu, William, Wittwer, Nicole L., Gargett, Tessa, Evdokiou, Andreas, Takhar, Prab, Rudd, Stacey E., Donnelly, Paul S., Brown, Michael P., Staudacher, Alexander H.

Get full text

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol by Hegi-Johnson, Fiona, Rudd, Stacey E, Wichmann, Christian, Akhurst, Tim, Roselt, Peter, Trinh, Jenny, John, Thomas, Devereux, Lisa, Donnelly, Paul S, Hicks, Rod, Scott, Andrew M, Steinfort, Daniel, Fox, Stephen, Blyth, Benjamin, Parakh, Sagun, Hanna, Gerard G, Callahan, Jason, Burbury, Kate, MacManus, Michael

“…BackgroundImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if 89Zr-durvalumab PET/CT can be used to interrogate the expression of…”
Get full text

In Vitro and In Vivo Evaluation of 89 Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy by Burvenich, Ingrid J G, Lee, Fook-Thean, Guo, Nancy, Gan, Hui K, Rigopoulos, Angela, Parslow, Adam C, O'Keefe, Graeme J, Gong, Sylvia J, Tochon-Danguy, Henri, Rudd, Stacey E, Donnelly, Paul S, Kotsuma, Masakatsu, Ohtsuka, Toshiaki, Senaldi, Giorgio, Scott, Andrew M

“…DS-8273a, an anti-human death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after specific…”
Get full text

In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy by Burvenich, Ingrid J G, Lee, Fook-Thean, Guo, Nancy, Gan, Hui K, Rigopoulos, Angela, Parslow, Adam C, O'Keefe, Graeme J, Gong, Sylvia J, Tochon-Danguy, Henri, Rudd, Stacey E, Donnelly, Paul S, Kotsuma, Masakatsu, Ohtsuka, Toshiaki, Senaldi, Giorgio, Scott, Andrew M

“…Background: DS-8273a, an anti-human death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after…”
Get full text